Drug Profile
Treprostinil prodrug transdermal - Corsair Pharma/United Therapeutics Corporation
Alternative Names: CO-254; Transdermal treprostinil prodrug patch - United Therapeutics/Corsair Pharma; VPD-380Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Corsair Pharma
- Developer United Therapeutics Corporation
- Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (Transdermal, Patch)
- 30 Jan 2018 Chemical structure information added
- 03 Jan 2018 United Therapeutics in-licenses portfolio of patents covering treprostinil prodrugs from Corsair Pharma